Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI programPUBT·Jul 15 at 11:52 AMSVRA-0.94%
Savara (SVRA) Stock May Trade At A Premium On Pipeline ExpectationsSimplywall·Jul 8 at 07:18 AMSVRA-0.94%
Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?Simplywall·Jun 29 at 02:50 PMSVRA-0.94%
Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?Simplywall·Jun 28 at 11:04 AMSVRA-0.94%
Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 millionPUBT·Jun 22 at 07:18 PMSVRA-0.94%
Savara Announces New Employment Inducement Grant | SVRA Stock NewsStockTitan·Jun 12 at 07:05 AMSVRA-0.94%
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock NewsStockTitan·May 19 at 11:15 PMSVRA-0.94%IBB-1.04%
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock NewsStockTitan·May 19 at 05:15 AMSVRA-0.94%XBI-1.25%
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock NewsStockTitan·May 18 at 05:55 AMSVRA-0.94%
LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)Tip Ranks·May 16 at 09:36 AMSVRA-0.94%PBE-0.66%
